BIOGEN INC. DL -,0005/ US09062X1037 /
2024-06-08 1:03:52 PM | Chg. 0.000 | Volume | Bid1:03:52 PM | Ask1:03:52 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
209.100EUR | 0.00% | - Turnover: - |
209.100Bid Size: - | 210.700Ask Size: - | 30.39 bill.EUR | - | - |
GlobeNewswire
06-03
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire
05-30
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire
05-22
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
02-12
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
2023-12-19
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
2023-12-15
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...